Home LiteratureArticle Details
PMID: 8521302 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits.

Molecular medicine (Cambridge, Mass.) ·Vol. 1 ·No. 4 ·1995-05-00 ·Pages 447-56

Vlassara H, Fuh H, Donnelly T, Cybulsky M

Abstract

Reactive glucose-protein intermediates and advanced glycation endproducts (AGEs) are shown to colocalize with atheromatous lesions and to trigger complex chemical and biological responses through interaction with vessel wall elements. In diabetes and renal insufficiency, atherosclerosis is common, as are elevated levels of serum and vascular tissue AGEs. In the present study, AGEs supplied exogenously to normal animals elicited vascular and renal pathology. Nondiabetic rabbits were injected intravenously with low doses of AGE-modified rabbit serum albumin (AGE-RSA, 16 mg/kg/day) for 4 months alone, or combined with a brief terminal period (2 weeks) of a cholesterol-rich diet (CRD) (2% cholesterol, 10% corn oil). AGE-RSA associated expression of vascular cell adhesion molecules and the development of atheromatous changes within the aorta were determined by immunohistology. The AGE content of aortic tissue increased by 2.2-fold in AGE-treated and by 3.2-fold in AGE + CRD-treated rabbits compared with normal saline-treated control rabbits (p < 0.025 and 0.001, respectively). Serum AGE levels in AGE groups rose up to 3-fold above the controls (p < 0.025 and p < 0.01). Ascending aortic sections from AGE-treated rabbits showed significant focal intimal proliferation, enhanced endothelial cell adhesion with infrequent intimal macrophages. oil-red-O staining lipid deposits and positive focal expression of vascular cell adhesion molecule-1 (VCAM-1), and intercellular adhesion molecule-1 (ICAM-1), a pattern not observed in controls. These AGE-induced changes were markedly enhanced in animals cotreated with AGEs and a brief period of CRD. Lesions consisted of multifocal atheromas, containing foam cells, massive lipid droplets, and strong endothelial expression of VCAM-1 and ICAM-1 restricted to the affected areas. This study provides in vivo evidence for a causal relationship between chronic AGE accumulation and atherosclerosis independent of diabetic hyperglycemia, and suggests the utility of this animal model for the study of diabetic vascular disease in relation to glycation.

MeSH Terms
Albumins Animals Aorta/metabolism,pathology Arteriosclerosis/chemically induced,metabolism,pathology Cholesterol/blood Diet, Atherogenic Glycation End Products, Advanced/blood,pharmacology Immunohistochemistry Intercellular Adhesion Molecule-1/biosynthesis Male Rabbits Vascular Cell Adhesion Molecule-1/biosynthesis
Chemicals
Albumins Glycation End Products, Advanced Vascular Cell Adhesion Molecule-1 Intercellular Adhesion Molecule-1 Cholesterol
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Vlassara H
Picower Institute for Medical Research, Manhasset, New York 11030, USA.
Fuh H
Donnelly T
Cybulsky M
References (24)
24 references, click to expand
  1. Modified assay for determination of hydroxyproline in a tissue hydrolyzate.
    Clin Chim Acta. 1980 Jun 10;104(2):161-7 PMID: 7389130
  2. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats.
    Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11704-8 PMID: 7972128
  3. Diabetes as an atherogenic factor.
    Prog Cardiovasc Dis. 1984 Mar-Apr;26(5):373-412 PMID: 6371895
  4. The pathogenesis of atherosclerosis--an update.
    N Engl J Med. 1986 Feb 20;314(8):488-500 PMID: 3511384
  5. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus.
    Am J Cardiol. 1987 Apr 1;59(8):750-5 PMID: 3825934
  6. The pathogenesis of atherosclerosis: atherogenesis and inflammation.
    Lab Invest. 1988 Mar;58(3):249-61 PMID: 3279259
  7. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling.
    Science. 1988 Jun 10;240(4858):1546-8 PMID: 3259727
  8. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.
    N Engl J Med. 1989 Apr 6;320(14):915-24 PMID: 2648148
  9. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties.
    J Exp Med. 1989 Oct 1;170(4):1387-407 PMID: 2551990
  10. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging.
    Proc Natl Acad Sci U S A. 1990 Nov;87(22):9010-4 PMID: 2247477
  11. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis.
    Science. 1991 Feb 15;251(4995):788-91 PMID: 1990440
  12. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes.
    J Clin Invest. 1991 Feb;87(2):432-8 PMID: 1991829
  13. Advanced glycosylation end products in patients with diabetic nephropathy.
    N Engl J Med. 1991 Sep 19;325(12):836-42 PMID: 1875967
  14. Immunochemical detection of advanced glycosylation end products in vivo.
    J Biol Chem. 1992 Mar 15;267(8):5133-8 PMID: 1371995
  15. Prevalence of, and risk factors for, angiographically determined coronary artery disease in type I-diabetic patients with nephropathy.
    Arch Intern Med. 1992 Dec;152(12):2450-5 PMID: 1456856
  16. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications.
    Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12043-7 PMID: 1465438
  17. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium.
    Arterioscler Thromb. 1993 Feb;13(2):197-204 PMID: 7678986
  18. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus.
    Am J Pathol. 1993 Dec;143(6):1649-56 PMID: 8256853
  19. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging.
    Lab Invest. 1994 Feb;70(2):138-51 PMID: 8139257
  20. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins.
    J Biol Chem. 1994 Apr 1;269(13):9889-97 PMID: 8144582
  21. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure.
    Lancet. 1994 Jun 18;343(8912):1519-22 PMID: 7911868
  22. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease.
    Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9436-40 PMID: 7937785
  23. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency.
    Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9441-5 PMID: 7937786
  24. Nonenzymatic browning in vivo: possible process for aging of long-lived proteins.
    Science. 1981 Jan 30;211(4481):491-3 PMID: 6779377
Article Info
Journal
Molecular medicine (Cambridge, Mass.)
Abbr.
Mol Med
ISSN
1076-1551
Published
1995-05-00
Pages
447-56
Language
English
Region
England
NLM ID
9501023
PMCID
PMC2229997
Subset
IM
Grants
NIA NIH HHS · AGO-6943 · United States
NIA NIH HHS · AGO-9453 · United States
NHLBI NIH HHS · HL 45563 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com